医薬品リファレンス
Eptifibatide
Eptifibatide is a medicine in the class cardiovascular. It is used for acute coronary syndrome.
- 薬効分類: Cardiovascular
- 効能・効果: acute coronary syndrome
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Cardiovascular
- ATCコード
- B01AC16
- 一般的な剤形
- 注射剤
- 一般的な規格
- 0.75 mg/ml, 2 mg/ml
- 既知の相互作用
- 42 (重大: 21 · 中等度: 10 · 軽度: 11)
- 商品名
- 3
- 国・市場
- 2
何に使われるか
作用のしくみ
Blocks binding of fibrinogen and von Willebrand factor to glycoprotein IIb/IIIa receptor on platelet surface
成人の通常用量（添付文書の要約）
Acute Coronary Syndromes: 180 mcg/kg IV bolus over 1-2 min, THEN 2 mcg/kg/min IV continuous infusion; continue infusion until hospital discharge or initiation of coronary artery bypass graft surgery (CABG), up to 72 hours
妊娠と授乳
- 妊娠
- Unknown Published reports are too few to assess risk; untreated heart attack can be fatal to mother and fetus. Bleeding is the main risk, especially near delivery. EU label: do not use unless clearly necessary.
- 授乳
- Unknown No milk data. A peptide likely destroyed in the infant gut. EU label: interrupt breastfeeding during treatment. LactMed: use with caution and watch the infant for bruising or bleeding. Given as a short IV course.
報告されている副作用
- Injection site reaction
- Thrombocytopenia
- Hypotension
- Bleeding
禁忌
- History of internal bleeding, intracranial hemorrhage or neoplasm, CVA, thrombocytopenia
- AV malformation or aneurysm, aortic dissection, severe HTN, acute pericarditis
- Other parenteral glycoprotein IIb/IIIa inhibitors
注意が必要な方
- In patients undergoing PCI, treatment may increase in major and minor bleeding at site of arterial sheath placement
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (42)
- Abrocitinib + Eptifibatide Major
- Acalabrutinib + Eptifibatide Major
- Acetylsalicylic acid + Eptifibatide Major
- Antithrombin alfa + Eptifibatide Major
- Antithrombin iii + Eptifibatide Major
- Apixaban + Eptifibatide Major
- Argatroban + Eptifibatide Major
- Betrixaban + Eptifibatide Major
- Bivalirudin + Eptifibatide Major
- Caplacizumab + Eptifibatide Major
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Eptifibatideの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- Dosing in older adults
- Pharmacokinetics
- Patient counselling points
- Food interactions
- IV preparation and dilution
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Eptifibatide used for?
Eptifibatide is a medicine in the class cardiovascular. It is used for Acute coronary syndrome, Percutaneous coronary intervention.
What side effects have been reported with Eptifibatide?
Injection site reaction, Thrombocytopenia, Hypotension, Bleeding.
Can Eptifibatide be taken in pregnancy or while breastfeeding?
Pregnancy: Unknown. Published reports are too few to assess risk; untreated heart attack can be fatal to mother and fetus. Bleeding is the main risk, especially near delivery. EU label: do not use unless clearly necessary. Breastfeeding: Unknown. No milk data. A peptide likely destroyed in the infant gut. EU label: interrupt breastfeeding during treatment. LactMed: use with caution and watch the infant for bruising or bleeding. Given as a short IV course.
What does Eptifibatide interact with?
MediHelp lists 42 known interactions for Eptifibatide. Major: 21 · Moderate: 10 · Minor: 11. The most serious include Abrocitinib, Acalabrutinib, Acetylsalicylic acid.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
